Clinical Trial Update: A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy for the Treatment of Traumatic Brain Injury and Hypoxic-Ischemic Encephalopathy [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating autologous mesenchymal stem cell therapy for traumatic brain injury and hypoxic-ischemic encephalopathy has completed and …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypoxic-ischemic Encephalopathy
• Traumatic Brain Injury

Drugs mentioned

• Hope Biosciences Autologous Mesenchymal Stem Cell Therapy (Autologous mesenchymal stem cell therapy)

Snippet

Sponsor: Hope Biosciences LLC | Conditions: Traumatic Brain Injury | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2026-01-15